The lawsuit alleges that MacroGenics and its executives made material misrepresentations about the safety data from its TAMARACK Phase 2 study of vobramitamab duocarmazine. On May 9, 2024, MacroGenics revealed that the drug was significantly more dangerous than previously represented, leading to a 77% decline in MacroGenics’ stock price.
Contact our attorneys for a no-cost case evaluation.